How do you distinguish benign from malignant extranodal small B-cell proliferations?

Area of Science:

• Hematology
• Oncology
• Pathology

Background:

• Diagnostic criteria for extranodal small B-cell lymphoproliferative disorders remain controversial.
• Distinguishing lymphomas from lymphoid hyperplasia is challenging but crucial for patient management.

Purpose of the Study:

• To review the diagnostic approaches for extranodal small B-cell lymphoproliferative disorders.
• To highlight the utility of a multiparameter strategy integrating clinical, morphologic, immunophenotypic, and genetic data.
• To identify areas for future research in molecular diagnostics and outcome prediction.

Main Methods:

• Morphological assessment including mass formation, architectural effacement, and cellular atypia.
• Immunophenotypic analysis for immunoglobulin light chain restriction and aberrant B-cell phenotypes.
• Evaluation of molecular techniques like Southern blot and PCR for gene rearrangements and translocations.

Main Results:

• A multiparameter approach effectively differentiates lymphomas from hyperplasia in most cases.
• Morphologic and immunophenotypic features strongly support a malignant diagnosis.
• The role of molecular techniques requires further validation due to technical limitations and clone significance ambiguity.

Conclusions:

• A comprehensive diagnostic strategy is essential for accurate classification of small B-cell lymphoproliferative disorders.
• Additional molecular markers are needed to define adverse outcomes and minimize misdiagnosis.
• Continued research is vital for advancing the understanding and management of these disorders.